Key Takeaways

• Robotic-assisted surgery device testing must evaluate the whole system, not just individual components.
• Traditional verification and validation often fail to address risks associated with packaging, sterilization, and cleanliness.
• New regulatory standards expect integrated, real-world validation.
• Millstone’s integrated testing model supports faster, more compliant submissions.

Why Robotic-Assisted Surgery Device Testing Must Evolve

Robotic-assisted surgery (RAS) is transforming modern medicine, delivering a level of precision that enhances outcomes across joint replacements, spinal procedures, soft tissue repairs, and other procedures. These systems enable less invasive techniques, faster recovery, and greater surgical consistency. But as RAS advances, traditional medical device testing methods are falling behind.

Standard verification and validation protocols rarely address how robotic workflows amplify biomechanical risks. Microscopic shifts during packaging, material changes after sterilization, or chemical residues from cleaning can all interfere with robotic calibration. Conventional test environments often fail to capture these performance problems.

When precision fails, devices face rework, regulatory delays, or real-world failure. For robotic-assisted surgery devices, these setbacks are more than technical. They delay market entry, slow surgeon adoption, and erode competitive position. That’s why robotic medical devices must be validated at the system level, under real-world conditions, with testing aligned to today’s evolving regulatory expectations. Achieving that requires a new, integrated approach.

Why Standard Robotic-Assisted Surgery Device Testing Falls Short

As robotic-assisted systems bring greater precision to surgery, they also introduce a greater risk of failure when components are compromised. Yet, many original equipment manufacturers (OEMs) still employ traditional verification and validation methods, which were designed for simpler, standalone implants or instruments.

These conventional protocols fall short in several ways:

• They test components in isolation, not as an integrated system.
• They overlook how robotic workflows magnify small biomechanical vulnerabilities.
• They overlook real-world factors, such as packaging-induced micro-movement, sterilization effects, or chemical residues, that can affect performance.
• They fail to incorporate feedback loops between mechanical and software validation.

For example, a robotic-assisted navigation tool might pass bench testing, only to fail calibration after being subjected to vibration during distribution. Or an instrument coating could degrade under EO sterilization, affecting precision at the surgical interface. Traditional mechanical or dimensional checks often overlook these issues, yet they have a direct impact on system-level performance and regulatory approval.

With the FDA and EU MDR requiring risk-based justification tied to intended use, OEMs must rethink how they validate robotic systems. They need test strategies that reflect real-world complexity, not just ideal lab conditions.

What Robotic-Assisted Surgery Device Testing Really Requires

Robotic-assisted surgery device testing goes beyond traditional mechanical or sterility validation. It represents a comprehensive strategy that evaluates how the entire system, including hardware, software, packaging, and sterilization, functions together under real-world surgical conditions.

This broader, integrated approach includes:

• Biomechanical testing of instruments and implants
• Packaging validation to confirm sterile barrier integrity and prevent distribution-related damage
• Software and human factors testing, aligned with IEC 80601-2-77 and FDA usability guidelines
• Cleanliness, extractables, and dimensional tolerance analysis to ensure safety and performance
• Cybersecurity and interoperability checks to validate essential performance under degraded or connected states

The goal is to ensure that robotic systems perform safely, accurately, and consistently throughout their entire lifecycle. Regulators increasingly expect this level of system-level, risk-based validation to support submissions, not just isolated performance metrics.

Medical Device Testing Challenges in Robotic Workflows

RAS systems operate with millimeter-level precision. That means even minor deviations caused by packaging stress, sterilization cycles, or handling can translate into significant surgical inaccuracies. Unlike conventional orthopedic tools, robotic instruments and implants are part of a system that relies on precise alignment, predictable responses, and seamless integration.

Here are five of the most critical biomechanical testing challenges in robotic-assisted surgery device testing workflows. OEMs must validate each one across the entire product lifecycle.

1. Packaging-to-Accuracy Coupling

Challenge: During shipping and handling, RAS instruments can experience micro-movements or shifts that alter their straightness, calibration datums, or geometry, which are critical to robotic targeting.

Required Testing: Perform distribution simulation (ISTA/ASTM), then conduct post-transit dimensional metrology using CMM, GD&T analysis, and optical inspection to confirm the device maintained its functional integrity.

2. Sterilization & Reprocessing Effects

Challenge: Repeated sterilization cycles, especially EO, gamma, or autoclave, can degrade coatings, alter material stiffness, or warp precision interfaces, particularly in hybrid materials or polymer-metal assemblies.

Required Testing: Perform multi-cycle sterilization and reprocessing simulations, followed by mechanical inspection and functional validation. Verify dimensions before and after each cycle to track changes over time.

3. Cleanliness & Particulate Validation

Challenge: Robotic-assisted surgery instruments and surgical trays must meet stringent requirements for particulate and cleanliness. Even trace residues can interfere with robotic sensors or jeopardize aseptic transfer in the OR.

Required Testing: Perform chemical residual and particulate analysis using cleanliness validation protocols aligned with ISO 19227, which regulators often apply as the current state of the art, even for non-implant instruments.

4. Packaging Integrity & Sterile Barrier Performance

Challenge: Packaging systems must preserve both sterile integrity and precise positioning of components through sterilization, shipping, and shelf life. Failure in seals, trays, or pouches can cause loss of calibration or render components non-compliant with regulations.

Required Testing: Conduct complete ISO 11607 packaging validations, including seal strength, dye, and bubble leak tests, and both accelerated and real-time aging. Integrate these tests with post-aging dimensional and mechanical assessments.

5. Dimensional & Mechanical Verification

Challenge: Robotic workflows demand exact interfaces between the instrument and the robot. Slight dimensional drift caused by thermal expansion, packaging strain, or repeated use can disrupt registration.

Required Testing: Dimensional inspection of critical features using CMM, micrometers, or high-resolution optical systems. GD&T analysis ensures key datums, angles, and straightness remain within robotic accuracy tolerances across the product lifecycle.

Regulatory Challenges for Robotic-Assisted Surgery Device Testing

The regulatory landscape for robotic-assisted surgery devices is evolving just as rapidly as the technology itself. Agencies such as the FDA and the European Commission now expect system-level validation, not just isolated data on mechanical or electrical performance.

To gain approval, OEMs must demonstrate how all components, including hardware, software, packaging, sterilization, and human interaction, perform together throughout the device’s lifecycle.

Here are ten critical regulatory areas now shaping robotic-assisted surgery device testing:

1. IEC 80601-2-77: Essential Performance

The FDA and EU recognize this standard, which defines mechanical and functional performance requirements for robotically assisted surgical systems. OEMs must demonstrate that the system maintains essential performance under real-world stressors, including transportation, sterilization, and aging.

2. No Prescriptive Accuracy Benchmark

Unlike traditional implants, robotic systems have no fixed dimensional tolerance. OEMs must define acceptable accuracy thresholds and justify them through risk-based evidence tied to intended surgical use.

3. Software and Mechanical Integration

Under the FDA’s 2023 software guidance and MDR Rule 11, mechanical test results must support software verification and validation. Misalignment between hardware data and software logic is grounds for rejection.

4. Human Factors and Usability Testing

The FDA’s Human Factors Engineering (HFE) guidance and the EU’s MDCG 2021-6 both emphasize the importance of safe and intuitive use in high-stakes environments. OEMs must validate packaging-to-use transitions, showing how users remove devices from trays, handle them aseptically, and dock them with robotic systems.

5. Cybersecurity and Safe States

The FDA’s 2025 cybersecurity requirements expect RAS systems to maintain essential performance under degraded states (e.g., loss of connectivity, sensor failure). Testing must show that the device responds predictably and safely under such conditions.

6. Sterilization and Reprocessing Validation

According to ISO 17664-1:2021, manufacturers must define functional acceptance criteria after sterilization and reprocessing. They must verify calibration accuracy, coating durability, and mechanical integrity across multiple cycles.

7. Cleanliness and Particulate Standards

Standards like ISO 19227 are increasingly applied not just to implants but also to instruments and robotic components, requiring chemical and particulate testing for every element that enters the sterile field.

8. Packaging Validation and Post-Distribution Checks

ISO 11607 now expects post-distribution evidence of both sterile barrier performance and dimensional stability. Packaging validation is incomplete without confirming that critical interfaces remain within tolerance after shipping and storage.

9. Lifecycle Change Control

The FDA and EU MDR both require risk-based revalidation anytime a change occurs to suppliers, sterilization methods, packaging, or software. Robotic systems are susceptible to changes in component alignment or materials.

10. Multi-Standard Evidence Integration

Submissions must now map testing results across multiple overlapping standards, such as IEC 80601, 60601, software, usability, cybersecurity, sterilization, cleanliness, and mechanical safety, to form a unified and audit-ready evidence package.

How Integrated RAS Medical Device Testing Bridges Technical and Regulatory Gaps

Robotic-assisted surgery device testing is no longer about checking individual boxes; it’s about optimizing the entire process. It focuses on proving how the entire system performs, holds up, and remains safe throughout its lifecycle while meeting increasingly shrinking development timelines. Yet most OEMs still rely on fragmented testing models, working with separate labs for packaging, sterilization, mechanical inspection, and cleanliness verification. This siloed structure causes delays, redundant testing, and fragmented documentation, all of which slow time to market and increase regulatory risk.

Millstone Medical Outsourcing addresses this challenge with a fully integrated testing model purpose-built for robotic-assisted surgery systems.

Millstone’s Integrated Testing Model

By unifying biomechanical testing, packaging validation, sterilization simulation, cleanliness analysis, and mechanical inspection under one roof and within a single quality system, Millstone helps OEMs accelerate timelines, avoid costly revalidation, and respond more quickly to regulatory feedback.

1. Technical Integrity, Built In

Millstone’s integrated workflow ensures every testing domain is cross-referenced, not isolated. That means:

• Teams perform packaging validations (ISO 11607) and conduct post-distribution dimensional checks to confirm that robotic alignment and calibration tolerances remain intact.
• Mechanical inspections follow sterilization cycles (EO, gamma, steam) to verify that materials, coatings, and joint interfaces maintain their performance after reprocessing.
• Cleanliness and particulate validation are conducted in parallel with usability testing to confirm aseptic handling readiness in accordance with ISO 19227 and FDA HFE guidance.
• Mechanical inspections are performed after environmental and sterilization exposure, ensuring real-world surgical accuracy aligns with the design intent.

The result: a proper system-level validation where form, function, and sterilization compatibility are confirmed together—not in isolation.

2. Regulatory Cohesion, Streamlined

Integrated testing also makes regulatory alignment, often the most complex part of submission, much easier to achieve. Instead of piecing together test data from multiple vendors, Millstone clients receive a unified test package that meets global regulatory expectations.

• Map evidence across IEC 80601-2-77, ISO 11607, ISO 17664, ISO 19227, and FDA guidance on HFE, cybersecurity, and reprocessing.
• Maintain a single quality system for all validations to reduce audit exposure and document inconsistencies
• Design test protocols with submission readiness in mind, avoiding costly rework or backtracking.
• Respond to agency feedback faster with consolidated, cross-functional data, reducing regulatory back-and-forth and avoiding launch delays.

With Millstone’s integrated RAS testing model, OEMs move faster, submit stronger, and launch with more confidence.

Raising the Standard for Robotic-Assisted Surgery Medical Device Testing

Robotic-assisted surgery devices are pushing the boundaries of precision, performance, and patient outcomes. But to bring these complex systems to market, OEMs must meet a new standard of evidence that goes beyond traditional testing to validate every component, interface, and real-world interaction.

To meet this new standard, OEMs must:

• Prove mechanical performance after sterilization and distribution.
• Demonstrate that packaging and cleanliness support aseptic workflows.
• Confirm that system-level integrity holds across software, hardware, and human factors.

Siloed testing can’t meet that demand. It creates gaps, delays, and risks.

Millstone’s integrated testing model meets the demands of this new era. By unifying packaging validation, sterilization conditioning, cleanliness analysis, and mechanical inspection within a single workflow and quality system, Millstone helps OEMs reduce time to market and avoid costly delays while delivering safer, more innovative products backed by stronger, faster submissions.

Testing success and regulatory approval for robotic-assisted surgery medical devices in the operating room hinge on proving that the entire system works effectively. Integrated testing is not merely a best practice, but the new standard.